New therapeutic approaches in pulmonary embolism

Respiration

Volumn 70, Issue 6, 2003, Pages 559-568

  Schellong, Sebastian M ^a   Schmidt, Benjamin A ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Coagulation; Thrombolysis; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A INHIBITOR; CERTOPARIN; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; MONOEMBOLEX; NADROPARIN; REVIPARIN; THROMBIN INHIBITOR; TINZAPARIN; XIMELAGATRAN;

BLEEDING; BLOOD CLOT LYSIS; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG TARGETING; ECHOCARDIOGRAPHY; FEASIBILITY STUDY; HEART DISEASE; HEART FUNCTION; HEART RIGHT VENTRICLE FAILURE; HEMODYNAMIC MONITORING; HUMAN; LUNG CIRCULATION; LUNG EMBOLISM; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; RESUSCITATION; REVIEW; RISK ASSESSMENT; SPECTRUM; THROMBUS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; CLINICAL TRIALS; HUMANS; PULMONARY EMBOLISM; THROMBECTOMY; THROMBOLYTIC THERAPY; VENOUS THROMBOSIS; VITAMIN K;

EID: 0942278980     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000075198     Document Type: Review

References (47)

1. Barritt DW, Jordan SC: Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet 1960;i:1309-1312.
2. Basu D, Gallus A, Hirsh J, Cade J: A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972;287:324-327.
3. Kearon C: Drug trials that have influenced our practice in the treatment of venous thromboembolism. Thromb Haemost 1997;78:553-557.
4. Bernardi E, Piccioli A, Oliboni G, Zuin R, Girolami A, Prandoni P: Nomograms for the administration of unfractionated heparin in the initial treatment of acute thromboembolism - An overview. Thromb Haemost 2000;84: 22-26.
5. Kearon C, Harrison L, Crowther M, Ginsberg JS: Optimal dosing of subcutaneous unfractionated heparin for the treatment of deep vein thrombosis. Thromb Res 2000;97:395-403.
6. Gallus A, Jackaman J, Tillett J, Mills W, Wycherley A: Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet 1986; ii:1293-1296.
7. Brandjes DP, Heijboer H, Buller HR, de Rijk M, Jagt H, ten Cate JW: Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992;327:1485-1489.
8. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. The Columbus Investigators. N Engl J Med 1997;337:657-662.
9. Simonneau G, Sors H, Charbonnier B, et al: A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. N Engl J Med 1997;337:663-669.
10. van Den Belt AG, Prins MH, Lensing AW, et al: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfrac-tionated heparin for venous thromboembo-lism. Cochrane Database Syst Rev 2000;(2): CD001100.
11. Huisman MV: Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: A randomized, double-blind, multinational study. J Thromb Haemost 2003;1(suppl 1):OC003.
12. Eriksson H, Wahlander K, Lundström T, Billing-Clason S, Schulman S, Investigators TI: Extended secondary prevention with the oral direct thrombin inhibitor ximelagatran for 18 months after 6 months of anticoagulation in patients with venous thromboembolism: A randomized, placebo-controlled trial. J Thromb Haemost 2003;1(suppl 1):OC005.
13. The Matisse Investigators: The MATISSE-PE trial, a multicenter, randomized, open study comparing once-daily fondaparinux (Arixtra®) with adjusted-dose intravenous unfractionated heparin (UFH) in the initial treatment of acute symptomatic pulmonary embolism (PE). J Thromb Haemost 2003;1(suppl 1):OC331.
14. Hirsh J, Dalen J, Anderson DR, et al: Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119(suppl 1):8S-21S.
15. Kearon C, Ginsberg JS, Kovacs MJ, et al: Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003;349: 631-639.
16. Crowther MA, Ginsberg JS, Julian J, et al: A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003;349:1133-1138.
17. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV: The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995;332:993-997.
18. Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS: Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998;279:458-462.
19. Schulman S, Rhedin AS, Lindmarker P, et al: A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med 1995;332:1661-1665.
20. Schulman S: Care of patients receiving long-term anticoagulant therapy. N Engl J Med 2003;349:675-683.
21. Hull R, Hirsh J, Jay R, et al: Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982;307:1676-1681.
22. Beyth RJ, Quinn LM, Landefeld S: Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998;105:91-99.
23. Kuijer PM, Hutten BA, Prins MH, Buller HR: Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999;159:457-460.
24. Schulman S, Granqvist S, Holmstrom M, et al: The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med 1997;336:393-398.
25. Kearon C, Gent M, Hirsh J, et al: A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999;340:901-907.
26. Agnelli G, Prandoni P, Santamaria MG, et al: Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 2001; 345:165-169.
27. Ridker PM, Goldhaber SZ, Danielson E, et al: Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003;348:1425-1434.
28. Seligsohn U, Lubetsky A: Genetic susceptibility to venous thrombosis. N Engl J Med 2001; 344:1222-1231.
29. Baglin T, Luddington R, Brown K, Baglin C: Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: Prospective cohort study. Lancet 2003;362:523-526.
30. van der Heijden JF, Hutten BA, Büller HR, Prins MH: Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database Syst Rev 2002;(1): CD002001.
31. Agnelli G, Prandoni P, Becattini C, et al: Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 2003;139:19-25.
32. Koopman MM, Buller HR: Short- and long-acting synthetic pentasaccharides. J Intern Med 2003;254:335-342.
33. Dalen JE, Alpert JS, Hirsch J: Thrombolytic therapy for pulmonary embolism: Is it effective? Is it safe? When is it indicated? Arch Intern Med 1997;157:2550-2556.
34. Kasper W, Konstantinides S, Geibel A, et al: Management strategies and determinants of outcome in acute major pulmonary embolism: Results of a multicenter registry. J Am Coll Cardiol 1997;30:1165-1171.
35. Arcasoy SM, Vachani A: Local and systemic thrombolytic therapy for acute venous thromboembolism. Clin Chest Med 2003;24:73-91.
36. Wood KE: Major pulmonary embolism: Review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. Chest 2002;121:877-905.
37. Kasper W, Konstantinides S, Geibel A, Tiede N, Krause T, Just H: Prognostic significance of right ventricular afterload stress detected by echocardiography in patients with clinically suspected pulmonary embolism. Heart 1997; 77:346-349.
38. Kasper W, Geibel A, Tiede N, et al: Distinguishing between acute and subacute massive pulmonary embolism by conventional and Doppler echocardiography. Br Heart J 1993; 70:352-356.
39. Goldhaber SZ, Visani L, De Rosa M: Acute pulmonary embolism: Clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999;353: 1386-1389.
40. Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W, the Management Strategies and Prognosis of Pulmonary Embolism-3 Trial Investigators: Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002;347: 1143-1150.
41. Reekers JA, Baarslag HJ, Koolen MG, Van Delden O, Van Beek EJ: Mechanical thrombectomy for early treatment of massive pulmonary embolism. Cardiovasc Intervent Radiol 2003; 26:246-250.
42. Muller-Hulsbeck S, Brossmann J, Jahnke T, et al: Mechanical thrombectomy of major and massive pulmonary embolism with use of the Amplatz thrombectomy device. Invest Radiol 2001;36:317-322.
43. Fava M, Loyola S, Huete I: Massive pulmonary embolism: Treatment with the hydrolyser thrombectomy catheter. J Vasc Interv Radiol 2000;11:1159-1164.
44. Schmitz-Rode T, Janssens U, Duda SH, Erley CM, Gunther RW: Massive pulmonary embolism: Percutaneous emergency treatment by pigtail rotation catheter. J Am Coll Cardiol 2000;36:375-380.
45. Murphy JM, Mulvihill N, Mulcahy D, Foley B, Smiddy P, Molloy MP: Percutaneous catheter and guidewire fragmentation with local administration of recombinant tissue plasminogen activator as a treatment for massive pulmonary embolism. Eur Radiol 1999;9:959-964.
46. Gulba DC, Schmid C, Borst HG, Lichtlen P, Dietz R, Luft FC: Medical compared with surgical treatment for massive pulmonary embolism. Lancet 1994;343:576-577.
47. Beer JH, Burger M, Gretener S, Bernard-Bagattini S, Bounameaux H: Outpatient treatment of pulmonary embolism is feasible and safe in a substantial proportion of patients. J Thromb Haemost 2003;1:186-187.